A pragmatic, randomized, phase III trial of biweekly vs. conventional use of trifluridine/tipiracil plus bevacizumab for refractory metastatic colorectal cancer
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms PRABITAS
- 15 Jan 2025 New trial record
- 14 Sep 2024 Trial design discussed in an abstract published at 49th European Society for Medical Oncology Congress